한국어
미제공
사전 컨퍼런스 데이
English
한국어
미제공
Explore the Agenda
일정 확인하기
Pre-Conference Day
Tuesday, 9 June 2026
Day One
Wednesday, 10 June 2026
Day Two
Thursday, 11 June 2026
8:00 am Check-In & Morning Coffee
Introduction to ADCs Day - ADC 기초 소개 데이
Gain a comprehensive overview of the fundamentals of ADC development, covering the history of the field, conjugation strategies, linker-payload basics, and antibody formats. The agenda is designed to establish a solid foundational understanding of ADCs prior to 2 days focused on innovations in ADCs from discovery to manufacturing. This day is intended for professionals who are new to the ADC field, at an early stage of ADC research, or seeking a structured refresher on core ADC principles.
Tracing the Evolution of ADCs: From Development History to Current Innovations in Antibody, Linker, Payload & Conjugation Technologies
9:00 am From Concept to Modality: Five Years That Have Reshaped the ADC Landscape
- Summary of the advancement in the last five years: Explore how ADCs have evolved into platform innovations, mirrored by surge in strategic global licensing and mergers and acquisitions
- Key ADC success driving the field: Discuss the clinical results that have reinforced therapeutic index and tumor biology -not potency alone-, driving success and deal value
- Industry shaping: Discover how large pharma will scale and commercialize ADCs, while small biotechs will continue to fuel platform and early-stage innovation
9:30 am Analyzing Current Trends With Antibody Formats, Payloads, Linkers & Conjugation Technologies to Explore Future Areas of Innovation
- Evaluating innovations in antibody formats and novel conjugates to bolster the success of tumor targeting
- Examining advances in payloads and linkers to improve potency and stability
- Investigating emerging conjugation technologies for efficient manufacturing of ADCs
Bispecific ADCs Day - 이중특이성 ADC 데이
Uncover key scientific and technical updates in the rapidly evolving area of bispecific ADCs. The agenda will address the drivers behind the innovation, as well as the science behind target selection, conjugation strategies, and the manufacturing of bispecific ADCs. Leave with all the knowledge you might need to develop your own successful and clinically viable Bispecific ADC. This day is intended for researchers currently developing bispecific ADCs and those seeking to expand or initiate research efforts in this area.
Defining Target Selection for Bispecific ADCs to Ensure Efficacy & Therapeutic Impact
9:00 am From Proximity Mapping to Therapeutics: Rational Target-Pair Selection With the MINTTM Platform for Bispecific ADCs
- Explore how MINT™ maps cell-surface protein microenvironments using proximity proteomics and machine learning to identify novel, co-localized target pairs for precision therapeutics
- Outline how applying MINT™ enables rational selection of tumor-associated proximity antigens (TAPAs), guiding the design of bispecific ADCs with improved tumor selectivity and reduced offtarget engagement
- Analyze how this proximity-driven framework supports the discovery and optimization of multiple bispecific ADC candidates, providing a systematic path from target-pair identification to preclinical validation
9:30 am Analyzing the Development of EGFRvii x MUC1 Bispecific ADC & Its Strategy in Improving Tumor Penetration
- Introducing EGFRviii and MUC1
- Exploring the dual combination of EGFRviii x MUC1
- Discussing better enrichment of ADC into the TME in the presence of vessel normalizer, PMC-403
10:00 am Morning Break
10:45 am Networking Session
Network with fellow attendees to share scientific insights on ADC discovery, development and manufacturing, ahead of the main conference days, as well as with global service providers and those working in the bispecific and TPD fields.
Analyzing ADC Design From Target to Payload Selection to Increase the Success Rate of Your ADC Molecule
11:30 am Reviewing Payload Selection to Understand Why Topoisomerase I Payloads Have Seen Success & Looking Forward to Combat Topo1 Resistance
- Identifying the reason behind the successes with Topoisomerase 1 ADCs
- Assessing the clinical and developmental benefits of Topoisomerase 1 ADCs
- Reviewing the emerging challenges with Topoisomerase 1 resistance and what that means for future development
Streamlining CMC & Bioanalysis for Bispecific ADCs to Overcome Added Complexity of Different Components & Prevent Downstream Errors
11:30 am Understanding How CMC Processes Differ for Bispecific ADCs & How to Adapt to Them to Reduce Manufacturing Complexity
- Mapping key CMC differences in bispecific ADCs and traditional ADCs to understand how to adapt manufacturing processes
- Implementing flexible process development and control strategies to prevent downstream challenges
- Leveraging platform technologies to reduce complexity and improve product quality
12:00 pm Learning How to Conduct Bioanalysis for Bispecific ADCs to Accurately Understand the Molecule as a Whole
- Understanding how different components affect the analysis and how that differs from a traditional ADC
- Exploring the differences in bioanalysis from traditional ADCs and how that can be adapted for bispecific ADCs
- Integrating multiple analytical technologies to gain a holistic understanding of pharmacokinetics and stability of the molecule
12:30 pm Lunch
1:30 pm Networking Session
Network with fellow attendees to share scientific ADC insights, ahead of the main conference days, as well as with global service providers and those working in the bispecific and TPD fields.
Reviewing Linker & Conjugation Chemistry to Develop Stable & Efficacious ADCs
2:15 pm Comparing Site-Specific, Homogeneous, Enzymatic & Chemical Conjugation & Their Individual Advantages & Potential in Improving ADC Stability & Efficacy
- Comparing reproducibility and DAR control of each conjugation strategy to select the ideal one for your ADC
- Discussing the advantages of each method in improving stability and scalability
- Assessing implications of each method on ADC performance
3:15 pm Introduction to ADCs Day Ends
Balancing Conjugation Chemistry With Bispecific ADC Design & Optimizing Payload Selection to Enhance Stability & Efficacy
2:15 pm Analyzing the Benefits of Using Cysteine Conjugation vs. Other Conjugation Technologies on Bispecific ADCs & Their Success Rate in Improving Stability of the Molecule
- Evaluating cysteine conjugation vs. lysine, enzymatic and site-specific technologies, and their effect on DAR ratio and uniformity
- Assessing the impact of each conjugation technology on ADC stability
- Exploring how each conjugation technology affects clinical performance
2:45 pm NEOK002 (ABL209): Redesigning an EGFRxMUC1 Bispecific TOP1i ADC With Promising Anti-Tumor Activity & Enhanced Therapeutic Window
- Selecting the target combination and validating
- Outlining how to differentiate NEOK002 from known EGFR and MUC1 targeting agents
- Exploring preclinical activity and toxicity of the bispecific ADC
3:15 pm Beyond Bispecific ADCs & The Next Wave: From Better Delivery to Checkmate Killing
- Exploring the evolution from traditional to bispecific ADCs
- Discussing the internalization-lethality gap and defining the biological ceiling of efficacy
- Predicting the next wave focused on overcoming resistance
3:45 pm Networking Session
Final chance to network with fellow attendees ahead of the main conference days.